Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $8 to $4.
Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price target from $8 to $4.